PRISM aims to operationalise readiness as a core execution variable.

The real “commercial launch” happens years before launch preparation officially begins. Once Phase III begins, your evidence ...

ConcertAI, a leading oncology real-world evidence and AI SaaS technology company, today unveiled Accelerated Clinical Trials (ACT), an enterprise agentic artificial intelligence (AI) platform designed ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...

Beyond the design, if enrollment slows due to seasonal effects or difficulty finding a niche patient group, a robust design activates a contingency plan that dynamically adjusts site selection based ...

In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of ...

At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., ...

TARPON SPRINGS, Fla., June 2, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...

The investment will support Biorce’s growing demand, international expansion, team growth, and continued development of its ...

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible. At the Clinical Trials in Oncology ...